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IntroDuctIon
Colorectal screening in Malta is a population-based screening 
programme modelled on the European Council guidelines of 
colorectal cancer management.1,2 Screening aims primarily 
at an early diagnosis when treatment is more likely to work 
(secondary prevention) and also for tertiary prevention with 
detection and management of metachronous lesions.
The use of Faecal Immunochemical Tests (FIT) to detect 
blood in stools is the primary screening tool. It has good patient 
compliance as patients do not need to undergo dietary or 
medication restriction unlike the guaiac-based Faecal Occult 
Blood test where Aspirin, anti-inflammatory medications and 
vitamin C preparations have to be stopped 7 days prior to test, 
and also undergo dietary restrictions.3,4 
In 2016, written invitations were sent to those born between 
1957-1959 (aged 59-61 years), to perform a FIT. Those who scored 
above 100ng/ml were then invited to undergo colonoscopy. 
MetHoD
Patient records and Colorectal Cancer Screening Programme 
datasheets for colonoscopies done at Gozo General Hospital 
between January and December 2016 were accessed. Data fields 
inspected retrospectively included patient demographics, date 
of the pre-assessment at the Lascaris deparment, waiting time to 
and date of colonoscopy, medication history, surgical, medical 
and family history and, relevant symptoms (including diarrhoea, 
constipation, bleeding, rectal irritation, mucus, tenesmus, 
abdominal pain). Other data included histology results, FIT 
values, MCV value, platelet count, bowel cleansing preparations 
which were used, extent of colonoscopic examination, as well 
as any colonoscopic findings including lesions or tumours or 
diverticuli, inflammation, bleeding, number and type of polyps, 
their location and whether the polyps were resected or not 
during the colonoscopy. Data was entered in an excel sheet for 
statistical processing.
results
362 patients with a FIT result above 100ng/ml presented for 
colonoscopy at Gozo General Hospital.
GenDer 
53.3% who had a positive FIT result were females while 46.7% 
were males.
syMptoMatIc versus asyMptoMatIc patIents
156 patients (43%) were asymptomatic while the remaining 206 
patients (57%) were symptomatic. 11 from 362 patients (3%) 
cases were diagnosed with colorectal adenocarcinoma; only 2 
of these were asymptomatic. Patients who were symptomatic 
included the following:
•	 119	from	362	patients	(33%)	complained	of	bleeding
•	 61	patients	(17%)	complained	of	tenesmus
•	 71	patients	(20%)	complained	of	rectal	irritation
•	 48	patients	(13%)	complained	of	abdominal	pain
•	 30	patients	(8%)	complained	of	change	in	bowel	habit	
– of which 10 patients suffered from diarrhoea and the 
remaining 20 patients suffered from constipation.
The following results show that each individual’s histology 
may have fallen in more than one of the mentioned categories. 
During colonoscopy specific patients had polyps of a different 
histological nature.
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abstract
Colorectal screening in Malta is a population-based screening 
programme using faecal immunochemical test as the primary 
screening tool. In this retrospective study, records and 
datasheets of patients undergoing screening colonoscopies at 
Gozo General Hospital in 2016 were inspected. The extracted 
data reflected national participation, as an integration 
between Mater Dei and Gozo General Hospitals was 
introduced, to reduce patients’ waiting time. Both Maltese and 
Gozitan patients were eligible for screening at Gozo General 
Hospital. Outcomes were collected into excel spreadsheets 
and statistically analysed. Participation rates, positivity rates 
and detection rates for colorectal cancers were compared 
with other European Union countries. Comparison showed 
that Malta has a higher detection rate for colorectal cancer 
for asymptomatic patients;- however, a significant number 
of cancer-positive patients were retrospectively also found to 
have been symptomatic.
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averaGe fIt values
The average FIT for asymptomatic patients was 184ng/ml.
polyp type overall asyMptoMatIc syMptoMatIc
Carcinoma 11 2 (0.6%) 9 (2.5%)
Metaplasia/Dysplasia 86 31 (8.6%) 55 (15.2%)
Adenoma 99 37 (10.2%) 62 (17.1%)
Other: Hyperplastic 
& Inflammatory polyps
300 110 (30.4%) 190 (52.5%)
polyp type overall asyMptoMatIc syMptoMatIc
Carcinoma 11 18% 82%
Metaplasia/Dysplasia 86 36% 64%
Adenoma 99 37.4% 62.6%
Other: Hyperplastic 
& Inflammatory polyps
300 36.7% 63.3%
Figure 1: Comparison of types of polyps identified in asymptomatic vs symptomatic 
patients as a percentage of a total of 362 patients undergoing colonoscopy. Patients in 
whom no polyps were identified were not listed in the above table.
Figure 2: % Asymptomatic vs % Symptomatic with positive findings at colonoscopy
The average FIT for symptomatic patients was 166ng/ml.
averaGe fIt In InDIvIDual cateGorIes of asyMptoMatIc patIents
Carcinoma 827
Metaplasia/Dysplasia 629
Adenoma 713
Other: Hyperplastic & Inflammatory polyps 373
averaGe fIt In InDIvIDual cateGorIes of syMptoMatIc patIents
Carcinoma 902
Metaplasia/Dysplasia 205
Adenoma 215
Other: Hyperplastic & Inflammatory polyps 288
FIT levels alone are not indicative of colonic tumours: whether 
benign or malignant. In fact this is why a patient with a positive 
FIT value is afterwards invited to undergo a colonoscopy. 
Latter will confirm the histological type of the polyps, as having 
an elevated FIT value, does not necessarily mean carcinoma. 
Patients with haemorrhoids or inflammatory bowel disease 
(IBD) can also have elevated FIT values. Sometimes FIT values 
are higher in these patients rather than in those patients with a 
colonic malignancy. The values obtained above could be due to 
the fact that most of the patients were asymptomatic at the time 
of screening but had either haemorrhoids or IBD or had both 
carcinomatous polyps and hyperplastic and inflammatory polyps.
otHer fInDInGs
Average time gap between the pre-assessment and endoscopic 
date was 43 days. During the procedure, bowel abnormalities 
and caecal intubation rate of 360 patients (from 362 patients) 
were recorded. Colonoscopy exit time was 22 minutes. 26 
colonoscopies did not have any exit time documented.
averaGe DuratIon of colonoscopy
•	 Less	than	10	min:	27	or	7.5%
•	 Between	11-30	min:	242	or	67%
•	 Between	31	and	60	min:	65	or	18%
•	 Over	1	hour:	2	or	0.6%
•	 Not	recorded: 26 or 7%
DIscussIon
In 2016, 14,844 letters were sent to the Maltese and Gozitan 
population, aged 59-61 years to participate in colorectal screening. 
557 (3.8%) invites were returned back undelivered. Therefore 
the total number of eligible invites were 14,287 (96%). From the 
latter, 12,209 accepted the invitation and their stool kits were sent 
to the lab. Those who had a positive FIT test were then invited to 
have a colonoscopy. All patients were asked whether they prefer 
undergoing their colonoscopy at either Mater Dei Hospital or 
Gozo General Hospital. Screening colonoscopies in Gozo helped 
in reducing waiting time; in fact the majority of patients that 
participated in the screening programme at Gozo, resided in Malta.
coMparIsIon of Data WItH otHer eu countrIes
The results of the Maltese population were compared to other 
European countries which either follow a non-population based 
colorectal screening i.e. Greece and Latvia, or a population-based 
screening i.e. Austria, Belgium, Croatia, Cyprus, Denmark, 
Finland, France, Hungary, Ireland, Germany, the Czech Republic, 
Italy, the Netherlands, Poland, Portugal, Slovenia, Spain, Sweden 
and the UK. Lithuania, which adopts a population-based 
colorectal screening, has been excluded from the analysis, as 
screening registries did not exist at that time and the call-recall 
system which ensures active invitation of the entire target 
population at regular intervals was not implemented. 5
A) Positivity Rate: Rates of positive screening test results, reflect 
the cut-off level chosen in each member state for the adopted test. 
These rates are consistent across the member states using gFOBT, 
ranging between 1.8% and 4.1%. However higher variability can be 
observed across member states adopting FIT, ranging between 3.3% 
to 9.8%. 931 out of 12,209 (7.6%) Maltese and Gozitan patients had 
a positive FIT. This is similar to the EU average.6 
B) Detection rates for colorectal cancers: Colorectal cancer 
detection rates across the member states ranged between 
0.09 – 0.19 % using gFOBT and 0.12 – 0.47% using FIT based 
programmes.6 In Malta and Gozo, patients who took part in the 
screening programme and who had a positive FIT (931) were 
then invited to undergo a colonoscopy. Out of 931, 723 (77.6%) 
patients accepted to undergo a colonoscopy. A total of 12 (1.7%) 
of these patients were diagnosed with colorectal cancer (Mater 
Dei and Gozo General Hospital; one was histologically diagnosed 
in Malta while the other eleven were diagnosed in Gozo. Of these 
eleven patients, two were Gozitan while the rest were Maltese).
Compared to the EU, a significant higher detection rate for 
colorectal cancer was noted. This could be due to the limited 
size of the gene pool as most people marry within the same 
population rather than foreigners.
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Overall, the detection rate and the positive predictive value for 
colorectal cancers and adenomas are influenced by characteristics of 
the screened population and by the screening protocol adopted.6,7
In European countries, detection rate of colorectal 
carcinomas and advanced adenomas is similar, where endoscopy 
screening is adopted either by flexible sigmoidoscopy or total 
colonoscopy. Detection of any other type of adenomas is higher 
with total colonoscopy rather than with flexible sigmoidoscopy. 
In general, the prevalence of target lesions is lower among 
screenees having previous negative examination reports. 
Independent of subjects’ screening history, the prevalence shows 
an increasing trend with age, both among men and women.6-8 
In the Maltese islands the average age for both adenoma and 
colorectal carincoma detection was 61 years.
partIcIpatIon rates
A) Gender: Women show a higher uptake than men in all 
countries using the faecal test while males show a higher uptake 
in those countries implementing endoscopy screening. 6,9 In 
this study, where the FIT test was used as the initial screening 
investigation, participation was highest amongst women (53.3% 
who had a positive FIT were females while 46.7% were males).
B) Age: In 2003, the EU Council recommended biennial 
screening with faecal occult blood testing to all subjects aged 50-
74 or, based on national prioritization for a narrower age band. 
Recently, based on a comprehensive review of available evidence, 
the EU Council is recommending that programmes should start 
screening between age 50 and 60, with a 2-year interval, if the 
screening test is gFOBT or FIT, or a 10-year interval, or more, if 
the screening test is flexible sigmoidoscopy or total colonoscopy, 
and to continue sending invitations to screen up to the age 
of 70–75 years.6,10 In 2016, the targeted age population in the 
Maltese islands included those between 59-61 years.
C) Screening Protocol: The type of screening protocol affects 
participation. Participation in a single invitation round is generally 
higher for programmes offering faecal tests as compared to 
programmes offering flexible sigmoidoscopy or total colonoscopy 
screening. However, a sigmoidoscopy or total colonoscopy can 
ensure a long lasting protection to those who attend.
From a public health point of view a proportion of non-
responders will attend at least once over repeated invitations. 
But non-invasive faecal tests for primary screening will require 
colonoscopy assessments of positive subjects. Issues related to 
colonoscopy capacity are also influencing the choice of the method, 
as well as the target age range, in different countries. For example 
Italy is providing a choice of different methods for screening to 
improve participation rates. Ideally all countries should adopt this 
method for a more reliable comparison.11 In 2016, 14,287 Maltese 
and Gozitan individuals received their invitation to undergo a 
FIT test. 12,209 (85%) accepted their invitation and participated. 
Participation rates across European countries exceeded the acceptable 
minimum of 45%, but neither country reached the desired target 
(>65%). Screening programs must employ specific strategies to 
attract the target population and encourage participation in screening 
programs.5 Although the participation rate in the Maltese islands was 
approximately 85%, one must remember that 557 invites were not 
delivered. So if the latter 557 invites were to be considered with the 
total, the participation rate decreases to 82%. In screening methods 
that employ faecal tests, patients need to be followed up, while in 
endoscopic methods, no follow-up is needed. From the 931 (6.3%) 
patients who resulted FIT-positive, 208 patients (22.3% of the FIT-
positive patients) did not undergo a colonoscopy. This clearly shows 
that with faecal tests there is the risk that patients do not undergo a 
colonoscopy and follow-up is lost.
The quality of screening reports has to be consistent and linked 
with the European health interview survey and national health 
interview surveys to obtain more precise information. Screening 
monitoring should be continuous and updated at regular intervals. 
Comparision of the data collected from various programmes needs 
to be enhanced. The coverage (by invitation and by examination) and 
the detection rates in different settings could be misleading unless due 
consideration is given to the different tests which are adopted, screening 
intervals and target ages that different programmes may adopt. 
Furthermore, opportunistic screening should also be accounted for.6
conclusIon
The high incidence of findings in asymptomatic patients and 
high percentage of symptomatic patients brings to question 
these patients’ lifestyle, their awareness and their management 
in primary care. In keeping with the study results, it is suggested 
that symptomatic patients, particularly those who experience 
rectal bleeding should be fast-tracked to a colorectal investigation, 
skipping the immunochemical screening phase. Absence of fast-
tracking may have led to the increased rate of colorectal cancer 
detection rate in the Maltese and Gozitan population. The increased 
detection rate of colorectal cancer may also be due to the limited 
size of the gene pool. Patients with a positive family history should 
seek medical advice for early screening even if asymptomatic.
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